Early change of prefrontal theta cordance and occipital alpha asymmetry in the prediction of responses to antidepressants

Bares, Martin; Novák, Tomáš; Vlček, Přemysl; Hejzlar, Martin; Brunovský, Martin

doi:10.1016/j.ijpsycho.2019.06.006

Cited by 12 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may influence midline theta band activity (and consequently theta cordance and ACC-localized activity) and has also been shown to differ in antidepressant treatment responders, who display higher baseline brain arousal levels and greater decreases in vigilance with treatment (Schmidt et al, 2017). The measure of cordance has also been questioned in terms of its physiological interpretation (Bares et al, 2019). Finally, while EEG has excellent temporal resolution, it has inherent spatial resolution limitations, which is particularly important for our source-localized ACC data.…”

Section: Limitationsmentioning

confidence: 99%

Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression

Salle

Phillips

Blier

et al. 2022

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Traditional antidepressants, which act on the serotonin, dopamine, and norepinephrine systems, require many weeks to produce a therapeutic effect and are not effective for every patient. A sub-anesthetic dose of the anesthetic agent ketamine, a glutamate N-methyl-Daspartate receptor antagonist, has been shown to produce a rapid and robust antidepressant effect in treatment-resistant major depressive disorder (MDD). As depressive symptoms typically return after one week following a single infusion, recent work has begun to focus on methods for prolonging the effects. Repeated infusions on a specific dosing schedule are being explored, however, the early identification of treatment responders and non-responders would be beneficial for optimized treatment selection within this population.The mechanisms underlying ketamine's rapid effects conceivably involve the regulation of altered glutamatergic signaling in MDD, though this is not yet completely understood.Understanding of the central mechanisms mediating ketamine's rapid antidepressant effects may be increased through the use of non-invasive electroencephalographic measures, including resting electroencephalography (EEG) and the mismatch negativity (MMN) event-related potential. These measures have been shown to be altered in depressed individuals and are sensitive to ketamine administration.The primary objectives of this study were to 1) examine acute changes in EEG-and MMN-derived indices, immediately post-and two hours postinfusion, with a sub-anesthetic ketamine dose in comparison to an active placebo (midazolam), and 2) to examine their relationships with early and sustained antidepressant treatment response to ketamine within an eight week clinical trial involving three study phases. IIIKetamine decreased measures of scalp-level alpha and theta resting activity, immediately postinfusion, and increased gamma immediately and two hours postinfusion. An increase in source-localized anterior cingulate activity two hours postinfusion was also observed. Regarding the MMN, ketamine reduced frontal amplitudes as well as theta event-related oscillations and source-localized peak frontal generator activity. Measures of resting theta and change in gamma, as well as left frontal MMN amplitude, theta event-related oscillations, baseline left phase locking factor, and baseline right inferior temporal lobe activity were predictive of decreases in depressive symptoms at both early and sustained treatment time points. Alpha power was predictive of decrease in suicidal ideation, though the relationship with baseline and early change in symptoms was stronger.These findings contribute to our understanding of the role of baseline and ketamineinduced changes in both resting and task-evoked electrophysiological measures, and may have the potential to act as non-invasive biomarkers of antidepressant response prediction to glutamatergic agents. IV PREFACEThis thesis is comprised of manuscripts (Chapters 2-3) which are in preparation for submission for publication in peer-reviewed jo...

show abstract

Section: Limitationsmentioning

confidence: 99%

Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression

Salle

Phillips

Blier

et al. 2022

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…FAA is therefore concluded to be a stable trait, not influenced by state and drug effects. This conclusion is in line with most of the literature (Allen et al, 2004;Bares et al, 2019;Bruder et al, 2008;Davidson et al, 2003;Deldin & Chiu, 2005;Gollan et al, 2014;Keune et al, 2011;Spronk et al, 2008;Sutton & Davidson, 1997;Tomarken et al, 1992), except for one study (Debener et al, 2000). Stability makes it suitable for sex specific treatment prediction under challenging circumstances such as state, time, the use of common antidepressive agents, and drug changes.…”

Section: What Can We Learn From State Trait and Drug Effects On Thesupporting

confidence: 89%

EEG biomarkers in depression: paving the way for stratified psychiatry

Vinne¹

View full text Add to dashboard Cite

show abstract

“…As context, much work has focused on degrees of asymmetry in alpha power to predict treatment outcome (Bruder et al, 1999(Bruder et al, , 2001(Bruder et al, , 2004(Bruder et al, , 2008Jaworska et al, 2012Jaworska et al, , 2014Tenke et al, 2011;Arns et al, 2016). Other studies have considered alpha activity as related to arousal regulation (Schmidt et al, 2017;Ulke et al, 2019), or have considered combinations of alpha and theta activity, either in models incorporating prefrontal theta cordance and occipital alpha asymmetry (Bares et al, 2019) or in a machine-learning paradigm using source localization as well as surface signals (Jaworska et al, 2019). Still other work has examined the loudness dependent auditory evoked potential (LDAEP), also called the intensity dependence of cortical auditory evoked potentials (IDAP) as an outcome predictor (Linka et al, 2004(Linka et al, , 2005.…”

Section: It Is Not Clear Why the Esc-based Atr Status Was Related To Bup Outcomes In Brite-mentioning

confidence: 99%

Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial

Cook¹,

Hunter²,

Caudill³

et al. 2020

Journal of Psychiatric Research

View full text Add to dashboard Cite

Management of Major Depressive Disorder (MDD) might be improved by a biomarker to predict whether a selected medication is likely to lead to remission. We previously reported on a quantitative electroencephalogram-based biomarker, the Antidepressant Treatment Response (ATR) index, that integrated recordings at baseline and after one week of treatment. The present study prospectively tested whether treatment directed by the biomarker increased the likelihood of remission; we hypothesized that continued treatment with a drug predicted to lead to remission (i.e., high ATR values) would be associated with better outcomes than if the drug was predicted not to lead to remission (i.e., low ATR values). We enrolled 180 adult outpatients with unipolar MDD from the community. After one week of escitalopram treatment to determine the biomarker, stratified randomization (high vs. low ATR) was used to assign subjects to either continued escitalopram or a switch to bupropion as a blinded control condition, for seven additional weeks. For the 73 evaluable subjects assigned to continued escitalopram treatment, the remission rate was significantly higher for those in whom ATR had predicted remission versus non-remission (60.4% vs. 30.0%, respectively, p=0.01). Accuracy was enhanced by combining 1-week depressive symptom change with ATR (68.6% vs 28.9%). This prospective validation study supports further development of the ATR biomarker, alone or together with early symptom change, to improve care by identifying individuals unlikely to remit with their current treatment, and support the decision to change treatment after one week rather than after failing a full, prolonged course of medication.

show abstract

Early change of prefrontal theta cordance and occipital alpha asymmetry in the prediction of responses to antidepressants

Cited by 12 publications

References 59 publications

Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression

Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression

EEG biomarkers in depression: paving the way for stratified psychiatry

Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial

Contact Info

Product

Resources

About